Главная страницаLBank Stocks
Insmed Inc
Insmed Inc

Insmed Inc (INSM)

24HВысокий$149.0724HНизкий$118.00
$144.25
+0.21%

Последнее обновление: 2026-11-20 10:30:33

Симуляция графика K-линий, фактические данные указаны на торговой странице

Ключевые данные

Открытие вчера
$119.50
Пред. закрытие
$144.25
Вчерашний диапазон
$118.00 - $149.07
Диапазон 52 нед.
$90.39 - $212.75
Объем торговли
13.4M
МС
$26.282B
P/E
--
EPS
$-2.81

Обзор компании

NASDAQ

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

СекторHEALTHCARE
ОтрасльBIOTECHNOLOGY
Штаб-квартира700 US HIGHWAY 202/206, BRIDGEWATER, NJ, UNITED STATES, 08807
СтранаUSA
Дата листинга1991-02-15
Конец финансового года2026-09-30
Акции в обращении219.38M
Код CIK1104506

Финансовые показатели

Индикатор2026-06-302026-03-312025-12-312025-09-30
Доход$425.486M$305.964M$263.843M$142.342M
Операционные расходы$67.212M$49.501M$44.22M$29.365M
Чистая прибыль-$13.242M-$163.563M-$328.485M-$370.021M
Чистая рентабельность-3.1%-53.5%-124.5%-260.0%
Прибыль на акцию--$-0.76$-1.54$-1.75
EBITDA$14.16M-$136.323M-$302.15M-$345.665M
Эффективная налоговая ставка-16.4%-0.9%-0.5%-0.4%

Часто задаваемые вопросы

Insmed Incorporated focuses on developing and commercializing therapies for serious and rare diseases. Its core products and pipeline are designed to address conditions with significant unmet medical needs, particularly in respiratory diseases like non-tuberculous mycobacterial (NTM) lung infections.
Insmed operates within the Healthcare sector, specifically in the Biotechnology industry. The company is involved in developing innovative therapeutic solutions targeting rare and life-impacting diseases.
Insmed’s revenue is primarily driven by the commercialization of its FDA-approved therapies, such as ARIKAYCE for treating NTM lung infections caused by Mycobacterium avium complex. Revenue growth also depends on expanding its market reach and advancing its clinical pipeline.
Investing in Insmed carries risks, including the uncertainty of clinical trial outcomes, regulatory approvals, and competition in the biotechnology space. Additionally, as a company focused on rare diseases, market size and adoption rates may impact its financial performance.
Insmed stands out by focusing on therapies that address rare diseases with significant unmet needs, particularly in the respiratory space. Its expertise in developing innovative drug delivery solutions and securing FDA approvals for niche treatments positions it uniquely within the biotechnology landscape.
No, Insmed does not currently pay dividends. As a growth-oriented biotechnology company, it reinvests earnings into research, development, and the commercialization of new therapies to drive long-term growth.
Insmed has a robust pipeline targeting rare and serious diseases. While the success of its clinical trials could greatly enhance growth opportunities, trial outcomes are inherently uncertain and subject to regulatory scrutiny, which presents both opportunities and risks for investors.
Regulatory decisions play a critical role in Insmed’s stock performance. FDA approvals, expanded label indications, or setbacks in clinical trials can significantly influence market sentiment regarding the company’s growth potential and valuation.
Предупреждение о рисках
  1. 1.Цены на акции могут сильно колебаться, инвестируйте осторожно. Прошлые результаты не гарантируют будущую доходность.
  2. 2.Торговля цифровыми активами сопряжена с рыночными, техническими и иными рисками. Пожалуйста, принимайте взвешенные решения и рационально распределяйте активы.
  3. 3.Информация на этой странице предназначена только для ознакомления и не является инвестиционной рекомендацией.